BIIB

Biogen (BIIB)

Biogen Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:BIIB

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2025/01/11	07 : 34	Edgar (US Regulatory)	Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership	NASDAQ:BIIB	Biogen Inc
2025/01/08	06 : 14	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/12/10	06 : 57	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/12/10	06 : 56	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/12/10	00 : 33	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:BIIB	Biogen Inc
2024/12/05	08 : 31	PR Newswire (US)	"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico	NASDAQ:BIIB	Biogen Inc
2024/11/28	09 : 31	PR Newswire (US)	"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea	NASDAQ:BIIB	Biogen Inc
2024/11/19	15 : 00	GlobeNewswire Inc.	Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity	NASDAQ:BIIB	Biogen Inc
2024/11/15	03 : 29	PR Newswire (US)	Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease	NASDAQ:BIIB	Biogen Inc
2024/11/15	01 : 23	GlobeNewswire Inc.	Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease	NASDAQ:BIIB	Biogen Inc
2024/11/08	06 : 23	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/11/05	06 : 39	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/10/31	08 : 30	GlobeNewswire Inc.	Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference	NASDAQ:BIIB	Biogen Inc
2024/10/31	05 : 45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BIIB	Biogen Inc
2024/10/31	05 : 31	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:BIIB	Biogen Inc
2024/10/30	19 : 55	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BIIB	Biogen Inc
2024/10/30	19 : 37	IH Market News	US Futures Rise as Tech Earnings Drive Market Optimism; Oil Prices Edge Up	NASDAQ:BIIB	Biogen Inc
2024/10/30	07 : 00	GlobeNewswire Inc.	Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases	NASDAQ:BIIB	Biogen Inc
2024/10/29	21 : 00	GlobeNewswire Inc.	Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer	NASDAQ:BIIB	Biogen Inc
2024/10/28	21 : 30	GlobeNewswire Inc.	Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025	NASDAQ:BIIB	Biogen Inc
2024/10/27	09 : 15	GlobeNewswire Inc.	Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024	NASDAQ:BIIB	Biogen Inc
2024/10/24	20 : 30	GlobeNewswire Inc.	Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference	NASDAQ:BIIB	Biogen Inc
2024/10/22	20 : 30	GlobeNewswire Inc.	Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024	NASDAQ:BIIB	Biogen Inc
2024/10/09	20 : 30	GlobeNewswire Inc.	Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients	NASDAQ:BIIB	Biogen Inc
2024/10/08	20 : 30	GlobeNewswire Inc.	New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA	NASDAQ:BIIB	Biogen Inc
2024/10/08	08 : 08	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/09/24	14 : 00	GlobeNewswire Inc.	UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024	NASDAQ:BIIB	Biogen Inc
2024/09/12	20 : 31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BIIB	Biogen Inc
2024/09/12	20 : 30	GlobeNewswire Inc.	Biogen Board Appoints Two New Independent Directors	NASDAQ:BIIB	Biogen Inc
2024/09/05	19 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc